Literature DB >> 19427497

Diastolic dysfunction as a link between hypertension and heart failure.

Anil Verma1, Scott D Solomon.   

Abstract

LVDD as an early measure of myocardial end-organ damage is commonly associated with hypertension and may well precede development of LVH in hypertension. About half of the patients presenting with heart failure have a normal ejection fraction, a clinical syndrome that is commonly referred to as HFPEF or diastolic heart failure and is commonly associated with impaired LV relaxation and increased diastolic stiffness. DD and HFPEF are commonly associated with advancing age and hypertension and increase in prevalence in association with these conditions, but there is a paucity of data on any specific therapeutic regimen. Hypertension control appears to be the most effective strategy in improving diastolic function and possibly for reducing the morbidity and mortality associated with HFPEF.

Entities:  

Mesh:

Year:  2009        PMID: 19427497     DOI: 10.1016/j.mcna.2009.02.013

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  19 in total

1.  Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and Akt.

Authors:  H Aceros; G Farah; L Cobos-Puc; A M Stabile; N Noiseux; S Mukaddam-Daher
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

2.  Mast Cell Inhibition Attenuates Cardiac Remodeling and Diastolic Dysfunction in Middle-aged, Ovariectomized Fischer 344 × Brown Norway Rats.

Authors:  Hao Wang; Jaqueline da Silva; Allan Alencar; Gisele Zapata-Sudo; Marina R Lin; Xuming Sun; Sarfaraz Ahmad; Carlos M Ferrario; Leanne Groban
Journal:  J Cardiovasc Pharmacol       Date:  2016-07       Impact factor: 3.105

3.  Maternal caffeine administration leads to adverse effects on adult mice offspring.

Authors:  Diana F Serapiao-Moraes; Vanessa Souza-Mello; Marcia B Aguila; Carlos A Mandarim-de-Lacerda; Tatiane S Faria
Journal:  Eur J Nutr       Date:  2013-01-05       Impact factor: 5.614

4.  NPY1-36 and PYY1-36 activate cardiac fibroblasts: an effect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4.

Authors:  Xiao Zhu; Delbert G Gillespie; Edwin K Jackson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-14       Impact factor: 4.733

5.  Relation of N-terminal pro-B-type natriuretic peptide with diastolic function in hypertensive heart disease.

Authors:  Imran Uraizee; Susan Cheng; Chung-Lieh Hung; Anil Verma; James D Thomas; Michael R Zile; Gerard P Aurigemma; Scott D Solomon
Journal:  Am J Hypertens       Date:  2013-06-22       Impact factor: 2.689

Review 6.  Current perspectives on systemic hypertension in heart failure with preserved ejection fraction.

Authors:  A Afşin Oktay; Sanjiv J Shah
Journal:  Curr Cardiol Rep       Date:  2014-12       Impact factor: 2.931

7.  Sex Difference in the Associations among Obesity-Related Indices with Incident Hypertension in a Large Taiwanese Population Follow-Up Study.

Authors:  Wen-Chi Lee; Pei-Yu Wu; Jiun-Chi Huang; Yi-Chun Tsai; Yi-Wen Chiu; Szu-Chia Chen; Jer-Ming Chang; Hung-Chun Chen
Journal:  J Pers Med       Date:  2022-06-15

8.  The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats.

Authors:  Que Liu; Lisa Adams; Anatoly Broyde; Rayne Fernandez; Alain D Baron; David G Parkes
Journal:  Cardiovasc Diabetol       Date:  2010-08-03       Impact factor: 9.951

Review 9.  Heart failure with preserved ejection fraction.

Authors:  James D Gladden; Wolfgang A Linke; Margaret M Redfield
Journal:  Pflugers Arch       Date:  2014-03-25       Impact factor: 3.657

10.  Association of P wave peak time with left ventricular end-diastolic pressure in patients with hypertension.

Authors:  Cengiz Burak; Metin Çağdaş; Ibrahim Rencüzoğulları; Yavuz Karabağ; Inanç Artaç; Mahmut Yesin; Tufan Çınar; Ibrahim Yıldız; Muhammed Suleymanoglu; Halil Ibrahim Tanboğa
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-04-05       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.